WO2001007397A1 - Procedimiento de obtencion de venlafaxina - Google Patents
Procedimiento de obtencion de venlafaxina Download PDFInfo
- Publication number
- WO2001007397A1 WO2001007397A1 PCT/ES2000/000255 ES0000255W WO0107397A1 WO 2001007397 A1 WO2001007397 A1 WO 2001007397A1 ES 0000255 W ES0000255 W ES 0000255W WO 0107397 A1 WO0107397 A1 WO 0107397A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- venlafaxine
- compound
- physiologically acceptable
- ethyl
- reaction
- Prior art date
Links
- 0 COc1ccc(C*)cc1 Chemical compound COc1ccc(C*)cc1 0.000 description 2
- AYXZUXPFYCNRFQ-UHFFFAOYSA-N CCOC(C(CN(C)C)c(cc1)ccc1OC)=O Chemical compound CCOC(C(CN(C)C)c(cc1)ccc1OC)=O AYXZUXPFYCNRFQ-UHFFFAOYSA-N 0.000 description 1
- PTBIZFFWYBCWMF-UHFFFAOYSA-N CN(C)C(C(C1(CCCCC1)O)c(cc1)ccc1OC)=O Chemical compound CN(C)C(C(C1(CCCCC1)O)c(cc1)ccc1OC)=O PTBIZFFWYBCWMF-UHFFFAOYSA-N 0.000 description 1
- MWJUYBUPJLZMQX-UHFFFAOYSA-N CN(CCc1c(C(CN)C2(CCCCC2)O)ccc(OC)c1)CC(C1(CCCCC1)O)c(cc1)ccc1OC Chemical compound CN(CCc1c(C(CN)C2(CCCCC2)O)ccc(OC)c1)CC(C1(CCCCC1)O)c(cc1)ccc1OC MWJUYBUPJLZMQX-UHFFFAOYSA-N 0.000 description 1
- ASYJSBPNAIDUHX-UHFFFAOYSA-N COc1ccc(C(C2(CCCCC2)O)C#N)cc1 Chemical compound COc1ccc(C(C2(CCCCC2)O)C#N)cc1 ASYJSBPNAIDUHX-UHFFFAOYSA-N 0.000 description 1
- PACGLQCRGWFBJH-UHFFFAOYSA-N COc1ccc(CC#N)cc1 Chemical compound COc1ccc(CC#N)cc1 PACGLQCRGWFBJH-UHFFFAOYSA-N 0.000 description 1
- NRPFNQUDKRYCNX-UHFFFAOYSA-N COc1ccc(CC(O)=O)cc1 Chemical compound COc1ccc(CC(O)=O)cc1 NRPFNQUDKRYCNX-UHFFFAOYSA-N 0.000 description 1
- USZSJPZSFKIORS-UHFFFAOYSA-N Cc(cc(CC(N(C)C)=O)cc1)c1OC Chemical compound Cc(cc(CC(N(C)C)=O)cc1)c1OC USZSJPZSFKIORS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- the present invention relates to a new method of obtaining venlafaxine, which is an antidepressant agent and which is the international common denomination (INN) of the product ( ⁇ ) -1- [2- (dimethylamino) -1- (4 - methoxyphenyl) ethyl] cyclohexanol, and / or its physiologically acceptable addition salts.
- INN international common denomination
- the object of the present invention is a method of obtaining venlafaxine easily adaptable. Industrial based on the use of easily accessible starting and intermediate products.
- the process object of the present invention for obtaining venlafaxine and / or its physiologically acceptable addition salts consists essentially in reacting a compound of general formula (II)
- R is a C1-C10 alkyl, aryl, aralkyl or cycloalkyl group of 3 to 6 carbon atoms, with an organomagnesian compound of the general formula (III)
- X means a halogen atom, preferably bromine and, if desired, a salt of venlafaxine obtained by reaction with a physiologically acceptable acid is formed.
- the compounds of formula (II) can be prepared by conventional methods, well known to the expert, among which those that are reflected in the reaction sequences of scheme 2, which start from p-methoxyphenylacetic esters.
- ester (IV) can be reacted with a dialkyl acetal of dimethylformamide to give rise to a ⁇ - (N, N) -dimethylamine) - ⁇ - (p-methoxyphenyl) ester acrylic (VI), which can be reduced, either by metal hydrides such as NaBH 4 or L ⁇ AIH 4 or by catalytic hydrogenation, to give the compound (II).
- a dialkyl acetal of dimethylformamide to give rise to a ⁇ - (N, N) -dimethylamine) - ⁇ - (p-methoxyphenyl) ester acrylic (VI), which can be reduced, either by metal hydrides such as NaBH 4 or L ⁇ AIH 4 or by catalytic hydrogenation, to give the compound (II).
- Intermediate (VI) can also be obtained by formulation of ester (IV) to give rise to intermediate (V), followed by the reaction of said intermediate (V) with dimethylamine.
- organomagnesian compounds of formula (III) they can be purchased commercially, as for example in the preferred case of pentamethylene-1,5-bis (magnesium bromide), or they can easily be prepared from the corresponding 1,5-dihalopentane by reaction with magnesium in an inert solvent, such as tetrahydrofuran.
- the reaction between the compound (II) and the organomagnesian compound (III) is carried out within an inert solvent, understood as an inert solvent, which in the opinion of the person skilled in the art does not react substantially with the reagents involved.
- an inert solvent understood as an inert solvent, which in the opinion of the person skilled in the art does not react substantially with the reagents involved.
- acyclic and cyclic ethers are preferred, with diethyl ether, tetrahydrofuran, dioxane, etc. being particularly preferred.
- reaction temperatures are between 0 o C and the reflux temperature of the selected solvent.
- the venlafaxine base can be transformed, by means of conventional techniques well known by the expert, into an addition salt with a physiologically acceptable inorganic or organic acid, among which, without limitation, there may be mentioned: hydrochloric, sulfuric , phosphoric, methanesulfonic, p-toluenesulfonic, citric, maleic, malic, fumaric, etc.
- a physiologically acceptable inorganic or organic acid among which, without limitation, there may be mentioned: hydrochloric, sulfuric , phosphoric, methanesulfonic, p-toluenesulfonic, citric, maleic, malic, fumaric, etc.
- hydrochloric acid as a physiologically acceptable acid to form the venlafaxine addition salt is preferred.
- a light stream of nitrogen is applied to a 500 ml balloon equipped with magnetic stirring and thermometer and 20 g of ethyl p-methoxyphenylacetate (0.109 mol) and 58.0 g of ethyl formate (0.721 mol) are mixed.
- the solution obtained is cooled to 0-5 ° C and 8.88 g of 60% sodium hydride (0.222 mol) are added portionwise for 3 hours 30 minutes. After the last load of sodium hydride, it is stirred for 2 hours and 30 minutes at room temperature. Again, it is cooled to 0-5 ° C and 100 ml of deionized water is added slowly, at internal temperature not exceeding 20 ° C.
- a light stream of nitrogen is applied to a 250 ml balloon equipped with magnetic stirring and thermometer and 21 g of ethyl ⁇ -formyl-p-methoxyphenylacetate (0.0945 mol), 80 ml of ethanol and 31.1 g are mixed of dimethylamine hydrochloride (0.38 mol). Then 7.4 g of potassium carbonate (0.054 mol) are added. The solution obtained is stirred at room temperature for 3 days. The solvent is evaporated to dryness in the rotary evaporator and 120 ml of water are added to the solid residue obtained. The pH is adjusted to 5-6 with 5 N hydrochloric acid and the product is extracted from the aqueous phase with 2 x 80 ml of dichloromethane. The organic extracts are dried with sodium sulfate and the solvent is removed under vacuum, obtaining a residue weighing 23.26 g and solidifying at room temperature (Rto: 98.7%)
- a light stream of nitrogen is applied to a 100 ml balloon equipped with magnetic stirring and 0.455 g of sodium borohydride (0.0120 mol) is mixed with 10 ml of ethanol. Then 1 g of ethyl ⁇ - (p-methoxyphenyl) - ⁇ - (dimethylamino) acrylate (0.0040 mol) is added. The mixture is stirred for 24 hours at room temperature and then 3 ml of water is added. Ethanol is removed in the rotary evaporator and 20 ml of water and 20 ml of dichloromethane are added to the residue. Stir and the phases are separated. The process continues with the organic phase. 20 ml of water are added, acidified to acidic pH and decanted.
- the aqueous phase is washed with 20 ml of dichloromethane and then basified to basic pH.
- the product is extracted from the phase aqueous with 20 ml of dichloromethane. Dry with sodium sulfate, filter and remove the solvent in vacuo to obtain 0.21 g of ethyl ⁇ -(p-methoxyphenyl) - ⁇ - (dimethylamino) (Rto: 21%)
- a light stream of nitrogen is applied to a 1L balloon provided with magnetic stirring and 6.06 g of lithium aluminum hydride (0.159 mol) is mixed with 300 ml of tetrahydrofuran.
- the suspension is cooled between -5 ° / 0 ° C and a solution consisting of 20 g of ethyl ⁇ - (p-methoxyphenyl) - ⁇ - (dimethylamino) acrylate (0.08 mol) obtained in example 3 and 75 ml of tetrahydrofuran.
- the mixture is stirred between -5 / 0 ° C for 7 hours and then kept at room temperature o.n. (14 hours) .
- a light stream of nitrogen is applied to a 500 ml balloon provided with a refrigerant, thermometer and magnetic stirring and 86.0 ml of pentamethylene bis (magnesium bromide) solution is charged in 0.5 solution of tetrahydrofuran (0.043 mol) , cooled to 10-20 ° C and 8.5 g of ethyl ⁇ - (p-methoxyphenyl) - ⁇ - (dimethylamino) propionate (0.0338 mol) obtained in example 6 and charged in 30 minutes Stir at room temperature for 3 hours 30 minutes.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002380854A CA2380854A1 (en) | 1999-07-27 | 2000-07-17 | A process for the preparation of venlafaxin |
SI200030552T SI1213279T1 (en) | 1999-07-27 | 2000-07-17 | Venlafaxine production process |
AU59874/00A AU5987400A (en) | 1999-07-27 | 2000-07-17 | Venlafaxine production process |
DK00945958T DK1213279T3 (da) | 1999-07-27 | 2000-07-17 | Fremgangsmåde til fremstilling af venlafaxin |
IL14766800A IL147668A0 (en) | 1999-07-27 | 2000-07-17 | A process for the preparation of venlafaxin |
AT00945958T ATE276229T1 (de) | 1999-07-27 | 2000-07-17 | Herstellungsverfahren für venlafaxin |
EP00945958A EP1213279B1 (en) | 1999-07-27 | 2000-07-17 | Venlafaxine production process |
US10/048,107 US6506941B1 (en) | 1999-07-27 | 2000-07-17 | Venlafaxine production process |
DE60013861T DE60013861T2 (de) | 1999-07-27 | 2000-07-17 | Herstellungsverfahren für venlafaxin |
IL147668A IL147668A (en) | 1999-07-27 | 2002-01-16 | Process for the preparation of venlafaxin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009901686A ES2152902B1 (es) | 1999-07-27 | 1999-07-27 | Procedimiento de obtencion de venlafaxina |
ESP9901686 | 1999-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001007397A1 true WO2001007397A1 (es) | 2001-02-01 |
Family
ID=8309382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2000/000255 WO2001007397A1 (es) | 1999-07-27 | 2000-07-17 | Procedimiento de obtencion de venlafaxina |
Country Status (12)
Country | Link |
---|---|
US (1) | US6506941B1 (es) |
EP (1) | EP1213279B1 (es) |
AT (1) | ATE276229T1 (es) |
AU (1) | AU5987400A (es) |
CA (1) | CA2380854A1 (es) |
DE (1) | DE60013861T2 (es) |
DK (1) | DK1213279T3 (es) |
ES (2) | ES2152902B1 (es) |
IL (2) | IL147668A0 (es) |
PT (1) | PT1213279E (es) |
SI (1) | SI1213279T1 (es) |
WO (1) | WO2001007397A1 (es) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696496B2 (en) | 2002-03-28 | 2004-02-24 | Synthon Bv | Low water-soluble venlafaxine salts |
US6717015B2 (en) | 2002-03-28 | 2004-04-06 | Synthon Bv | Venlafaxine besylate |
KR20130141717A (ko) * | 2006-07-06 | 2013-12-26 | 어레이 바이오파마 인크. | AKT 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타[d]피리미딘 |
US9359340B2 (en) | 2006-07-06 | 2016-06-07 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040186310A1 (en) * | 2001-06-22 | 2004-09-23 | Kim Keun-Sik | Process for preparation of cyclohexanol derivatives |
KR20080056311A (ko) * | 2005-10-19 | 2008-06-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 고순도1-[2-디메틸아미노-(4-메톡시페닐)에틸)시클로헥산올염산염의 제조 방법 |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
NZ597550A (en) * | 2009-07-16 | 2013-08-30 | Cipla Ltd | Process for the preparation of o-desmethyl venlafaxine and intermediate for use therein |
CN115650863A (zh) * | 2022-09-05 | 2023-01-31 | 上海博纳赛恩医药研发有限公司 | 制备文拉法辛盐酸盐的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8802131A1 (es) * | 1982-12-13 | 1988-04-01 | American Home Prod | Un procedimiento para la produccion de derivados de feniletilamina. |
GB2227743A (en) * | 1989-02-01 | 1990-08-08 | Wyeth John & Brother Ltd | Cyclohexanol derivatives |
-
1999
- 1999-07-27 ES ES009901686A patent/ES2152902B1/es not_active Expired - Fee Related
-
2000
- 2000-07-17 PT PT00945958T patent/PT1213279E/pt unknown
- 2000-07-17 SI SI200030552T patent/SI1213279T1/xx unknown
- 2000-07-17 CA CA002380854A patent/CA2380854A1/en not_active Abandoned
- 2000-07-17 EP EP00945958A patent/EP1213279B1/en not_active Expired - Lifetime
- 2000-07-17 AU AU59874/00A patent/AU5987400A/en not_active Abandoned
- 2000-07-17 DE DE60013861T patent/DE60013861T2/de not_active Expired - Fee Related
- 2000-07-17 ES ES00945958T patent/ES2226877T3/es not_active Expired - Lifetime
- 2000-07-17 US US10/048,107 patent/US6506941B1/en not_active Expired - Fee Related
- 2000-07-17 IL IL14766800A patent/IL147668A0/xx active IP Right Grant
- 2000-07-17 AT AT00945958T patent/ATE276229T1/de not_active IP Right Cessation
- 2000-07-17 WO PCT/ES2000/000255 patent/WO2001007397A1/es active IP Right Grant
- 2000-07-17 DK DK00945958T patent/DK1213279T3/da active
-
2002
- 2002-01-16 IL IL147668A patent/IL147668A/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8802131A1 (es) * | 1982-12-13 | 1988-04-01 | American Home Prod | Un procedimiento para la produccion de derivados de feniletilamina. |
GB2227743A (en) * | 1989-02-01 | 1990-08-08 | Wyeth John & Brother Ltd | Cyclohexanol derivatives |
Non-Patent Citations (1)
Title |
---|
YARDLEY J.P. ET AL.: "2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine derivatives: Synthesis and antidepressant activity", J. MED. CHEM., vol. 33, 1990, pages 2899 - 2905, XP000891765 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696496B2 (en) | 2002-03-28 | 2004-02-24 | Synthon Bv | Low water-soluble venlafaxine salts |
US6717015B2 (en) | 2002-03-28 | 2004-04-06 | Synthon Bv | Venlafaxine besylate |
KR20130141717A (ko) * | 2006-07-06 | 2013-12-26 | 어레이 바이오파마 인크. | AKT 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타[d]피리미딘 |
KR101495408B1 (ko) * | 2006-07-06 | 2015-02-25 | 어레이 바이오파마 인크. | AKT 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타[d]피리미딘 |
KR101578877B1 (ko) * | 2006-07-06 | 2016-02-22 | 어레이 바이오파마 인크. | AKT 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타[d]피리미딘 |
US9359340B2 (en) | 2006-07-06 | 2016-06-07 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
ES2152902A1 (es) | 2001-02-01 |
EP1213279B1 (en) | 2004-09-15 |
ES2152902B1 (es) | 2001-08-16 |
DE60013861D1 (de) | 2004-10-21 |
US6506941B1 (en) | 2003-01-14 |
ES2226877T3 (es) | 2005-04-01 |
IL147668A0 (en) | 2002-08-14 |
IL147668A (en) | 2006-08-20 |
AU5987400A (en) | 2001-02-13 |
PT1213279E (pt) | 2005-01-31 |
CA2380854A1 (en) | 2001-02-01 |
EP1213279A1 (en) | 2002-06-12 |
DK1213279T3 (da) | 2005-01-10 |
SI1213279T1 (en) | 2005-04-30 |
ATE276229T1 (de) | 2004-10-15 |
DE60013861T2 (de) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2523570T3 (es) | Aril-ciclohexil-tetraazabenzo[e]azulenos | |
US20060079715A1 (en) | Production of 2-amino-2-(4-alkylphenyl)ethyl]propane-1,3-diols | |
MX2009001019A (es) | Proceso para preparacion de ciclopropilaminas opticamente activas. | |
JPH05213838A (ja) | フルオキセチンの製法 | |
US20110257401A1 (en) | Process for producing optically active carboxylic acid | |
WO2001007397A1 (es) | Procedimiento de obtencion de venlafaxina | |
KR100915551B1 (ko) | 3-히드록시 피롤리딘 및 이의 유도체의 효율적 제조방법 | |
JP3885497B2 (ja) | 1,2,4−ブタントリオールの製造方法 | |
CA2184500A1 (en) | Synthesis of compounds with predetermined chirality | |
US20040102651A1 (en) | Synthesis of 3-aminomethyl-1-propanol, a fluoxetine precursor | |
JP3158507B2 (ja) | 光学活性3−フェニル−3−ヒドロキシプロピオン酸エステルの製造方法 | |
JPH0228144A (ja) | ペプチド誘導体合成に有用な立体特異性中間体の製法 | |
JP4111756B2 (ja) | 3,3,3−トリフルオロ−2−ヒドロキシプロピオン酸およびその誘導体の製造方法 | |
JP4540197B2 (ja) | (e)−3−メチル−2−シクロペンタデセノンの製造法 | |
JP2002527500A (ja) | 光学活性シクロヘキシルフェニルグリコール酸及びそのエステル | |
JP2002505317A (ja) | キラルβ−アミノ酸の合成 | |
TWI309639B (es) | ||
WO2002020461A1 (fr) | 3-amino-1-indanole, technique de synthese de ce compose et procede de resolution optique | |
JP4745655B2 (ja) | 5−ノルボルネン−2−カルボン酸およびそのエステルの製造方法 | |
JP3743867B2 (ja) | 2−フルオロシクロプロパンカルボン酸類の製造法 | |
CA2584349A1 (en) | Process for the preparation of 2-methylspiro(1,3-oxathiolane-5,3') quiniclidine | |
JP2002522533A (ja) | エナンチオ選択的合成 | |
US6207854B1 (en) | Preparation of 3-amino-3-cyclopropylpropanoate esters | |
US7763754B2 (en) | Process for producing (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol | |
JP2005060231A (ja) | 新規酸性光学分割剤の製造方法およびこれを用いたアミン類の光学分割 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 147668 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10048107 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2380854 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000945958 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945958 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000945958 Country of ref document: EP |